Search Results - "Duccio Papanti, G."

Novel psychoactive substances of interest for psychiatry by Schifano, Fabrizio, Orsolini, Laura, Duccio Papanti, G., Corkery, John M.

“…Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids,…”
Get full text

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset by Chiappini, Stefania, Vickers-Smith, Rachel, Harris, Daniel, Papanti Pelletier, G Duccio, Corkery, John Martin, Guirguis, Amira, Martinotti, Giovanni, Sensi, Stefano L, Schifano, Fabrizio

“…Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese…”
Get full text

Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach by Arillotta, Davide, Floresta, Giuseppe, Papanti Pelletier, G Duccio, Guirguis, Amira, Corkery, John Martin, Martinotti, Giovanni, Schifano, Fabrizio

“…Glucagon-like peptide-1 (GLP-1) is involved in a range of central and peripheral pathways related to appetitive behavior. Hence, this study explored the…”
Get full text

Novel psychoactive substances: the pharmacology of stimulants and hallucinogens by Schifano, Fabrizio, Papanti, G Duccio, Orsolini, Laura, Corkery, John M

“…There are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets' scenarios. The paper aims at…”
Get more information

Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review by Vento, Alessandro E., Kotzalidis, Georgios D., Cacciotti, Marta, Papanti, G. Duccio, Orsolini, Laura, Rapinesi, Chiara, Savoja, Valeria, Calabrò, Giuseppa, Del Casale, Antonio, Piacentino, Daria, Caloro, Matteo, Girardi, Paolo, Schifano, Fabrizio

“…Background: Quetiapine, an atypical antipsychotic endowed with weak dopamine antagonist, potent 5-HT 2A -blocking, partial 5-HT 1A -agonist, anti-H 1…”
Get full text

Is there a potential of misuse for Magnolia officinalis compounds/metabolites? by Schifano, Fabrizio, Guarino, Valentina, Papanti, Duccio G., Baccarin, Jacopo, Orsolini, Laura, Corkery, John M.

“…Objective Magnolia bark contains magnolol, metabolized to tetrahydromagnolol and honokiol, with both GABA‐ergic/cannabimimetic activities, hence of possible…”
Get full text

Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward by Chiappini, Stefania, Papanti Pelletier, G Duccio, Vickers-Smith, Rachel, Corkery, John M, Guirguis, Amira, Martinotti, Giovanni, Schifano, Fabrizio

Get more information